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Verotoxin-l Promotes Leukocyte Adhesion to Cultured Endothelial Cells Under Physiologic Flow Conditions
By Marina Morigi, Gianluca Micheletti, Marina Figliuzzi, Barbara Imberti, Mohamed A. Karmali, Andrea Remuzzi, Giuseppe Remuzzi, and Carla Zoja
Hemolytic uremic syndrome (HUS), which is the most common cause of acute renal failure in infants and small children, is caused by verotoxin (m)-producing Escherichia coli infection. Endothelial injury determines microvascular thrombosis and evidence is available from recent studies that suggests that leukocyte activation participates in endothelial damage. We studied here the effect of VT-1 on leukocyte adhesion t o vascular endothelium under physiologic flow conditions. Human umbilical vein endothelial cells (HUVECs) were incubated for 24 hours with VT-1 (0.1, 1, and 10 pmol/ L) and then exposed t o a total leukocyte suspension in a parallel plate flow chamber under laminar flow conditions (1.5 dyneslcm'). Adherent cells were counted by digital image processing. Results showed that VT-1 dose-dependently increased the number of adhering leukocytes t o HUVECs as compared with unstimulated cells. The adhesive response elicited by VT-1 was comparable to that of interleukin-1P (IL-lp), one of the most potent inducers of endothelial cell adhesiveness. Exposure of HUVECs t o VT-1 did not affect ESEARCH IN THE last few years has established a link between enteric infection with verotoxin (VT)-producing Escherichia coli (VTEC) and hemolytic uremic sindrome (HUS),'-' a disorder of thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure that mainly affects infants and small ~hildren.~ VT (or Shiga-like toxins, a family of E coli-derived toxins)' bind to a specific receptor identified as the glycosphingolipid globotriaosylceramide (Gb$' on leukocytes and endothelial cells of target organs, and cell susceptibility to VT damage is a function of Gb, expression on cell In North America and Western Europe, 90% of children with epidemic diarrhea-associated HUS have evidence of VTEC infection.'.'" It is now clear that vascular endothelial cell injury is central to the full development of microangiopatic lesions," but the complex mechanism(s) underlying endothelial perturbation and damage in this disease is far from being defined. The toxicity of VT-1 on vascular endothelial cells in culture is remarkably potentiated by leukocyte-derived tumor necrosis factor a (TNFa), which also contributes to upregulate Gb, receptors on endothelial cell^.^^^^ TNFa-induced upregulation of VT-l receptors on endothelial cells depends on galactosyl transferase induction13 by a mechanism independent of protein kinase C activation. Endothelial surface expression of VT-I receptor then orients subsequent localization of microvascular damage, as documented by animal experiment^.'^ Thus, TNFa appears a crucial molecule in the sequence of events leading to endothelial damage in VTEC-associated forms of childhood HUS. Finding that circulating inflammatory cells including macrophages (the main source of TNFa in humans) constitutively express VT-I receptors and release TNFa in vitro upon VT-l binding to its specific receptorst5 led investigators to consider the possibility that, in HUS, interaction between activated leukocytes and endothelial cells is indeed instrumental to the development of microvascular injury. Preliminary data have suggested that endothelial damage might critically depend the number of rolling leukocytes, which was similar to that of control values. To examine the role of adhesion molecules in VT-l-induced leukocyte adhesion, HUVECs were incubated with mouse monoclonal antibodies against E-selectin, intercellular adhesion molecule-l (ICAM-l), and vascular cell adhesion molecule-l (VCAM-1) before adhesion assay. Functional blocking of E-selectin, ICAM-1, and VCAM-1 on endothelial cells significantly inhibited VT-1 -induced increase in leukocyte adhesion. In some experiments, before VT-1 incubation, HUVECs were pretreated for 24 hours with tumor necrosis factor a (TNFa; 100 UlmL), which is known t o increase VT receptor expression on HUVECs. The number of adhering leukocytes on HUVECs exposed t o TNFa and VT-1 significantly increased as compared with HUVECs incubated with VT-1 and TNFa alone. These results suggest that VT-1 modulates leukocyte-endothelium interaction, thus increasing leukocyte adhesion and upregulating adhesive proteins on endothelial surface membrane. on neutrophil-specific proteases, particularly elastases, released by activated hyperadherent leukocytes." Consistent with this possibility are findings that levels of plasma leukocyte elastase were remarkably higher than normal in children with diarrhea-associated HUS, which presumably reflected leukocyte activation in vivo."
The present study was designed to clarify whether VT-l directly modulated leukocyte adhesion to endothelial cells. Experiments were planned to address (1) the effect of VT-1 on leukocyte adhesion to cultured endothelial cells exposed to flow conditions that mimic postcapillary venule circulation; (2) the molecular determinants of VT-1 -induced leukocyte adhesion; and (3) the possible role of TNFa of amplifying VT-l -induced leukocyte adhesion to endothelial cells.
MATERIALS AND METHODS
Endothelial cell culture. Endothelial cells were obtained from human umbilical veins (HUVECs) by collagenase digestion according to the method of Jaffe et al.'* The cells were grown in Medium 199 (GIBCO, Grand Island, NY) supplemented with 10% newborn calf serum (GIBCO), 10% human serum, and antibiotics. Cultures were grown at 37°C in 5% C02-95% air. Confluent HU-
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VECs were routinely used for experiments between the first and fifth passage. Cultured cells were identified as endothelial by their cobblestone morphology and the presence of von Willebrand factor, using indirect immunofluorescence microscopy. HUVECs were plated on 60-X 20-mm plastic coverslips (Thermanox; Nunc, Naperville, IL) coated with bovine gelatin and used 2 days after reaching confluence. HUVECs were incubated for 24 hours with control medium (M199 plus 10% fetal calf serum ) or VT-I (0. I , I , and 10 pmoVL). Purified VT-I was prepared in the laboratory of Dr M.A.
Kannali (1.2 mg proteidml; CD50 vero-cells: titer, 10-'to 10" 1. ' Endotoxin content of the VT-I preparation was determined to less than 0.05 EU/mL using Limulus amoebocyte lysate assay (E-Toxic; Sigma Chemicals, St Louis, MO) at detection levels of 0.05 to 0.10 EU/mL. HUVECs stimulated for 4 hours with recombinant human interleukin-lp (IL-lp; 100 U/mL; 5 X 10' U/mg protein; Boheringer In additional experiments, HUVECs were pretreated for 24 hours with human recombinant TNFa ( 100 or 300 UlmL; 6. I X IO7 U/mg protein; gift from BASF KNOLL, Ludwigshafen, Germany) before incubation for 24 hours with VT-1 (10 pmol/L).
Parallel-plateflow chamber. For adhesion experiments, we used a parallel-plate flow chamber as previously described.'".'' Briefly, the chamber is composed of two parallel surfaces, a coverslip coated with HUVECs at confluence and a flat surface machined from polymethylmethacrylate, separated by a 250-pm thick silicon rubber gasket, leaving a rectangular surface (30 X 13 mm) exposed to flow. An inlet and an outlet channel distribute the fluid uniformly along the entrance side of the adhesion surface. After assembling with the HUVEC monolayer, the chamber is placed on the stage of an inverted phase-contrast microscope with a termostated hood to maintain the temperature at 37°C. The microscope is connected with a videorecording system (VHS; Panasonic, Osaka, Japan).
Adhesion assay under Pow conditions. Before adhesion experiments, a leukocyte suspension was prepared from fresh venous blood collected on EDTA (final concentration, 5 mmol/L) and diluted with an equal volume of cold saline solution. The blood samples were centrifuged at 200g for 10 minutes at 4"C, the cell pellet was resuspended in 4 vol of Emagel (Behringwerke AG, Marburg, Germany), and erythrocytes were sedimented at 4°C for 40 minutes. Supernatant was removed and centrifuged at 500g for 7 minutes at 4°C and the pellet washed twice by centrifugation with saline. Remaining erythrocytes were removed by ammonium chloride lysis at 4°C and centrifugation. After this procedure, the cell viability, measured by trypan blue exclusion, was greater than 95%. Cells were then resuspended in culture medium at a final concentration of 10" cells/mL.
Leukocyte suspension was pumped through the chamber on HU-VEC monolayers, at controlled flow rates, using a syringe pump (Harvard Apparatus lnc, South Natick, MA). After an initial perfusion of the flow chamber at 0.6 dynes/cm' for 2 minutes for equilibration, the total leukocyte suspension was perfused through the chamber at a constant flow rate (1.5 dynes/cm*) and images recorded using a video recording system. After 10 minutes of perfusion, the flow rate of the cell suspension was increased so that wall shear stress increased from l .S to 3.0 dyneslcm' to measure the number of cells rolling on the HUVEC surface. At this flow rate, leukocytes rolling on the adhesion surface are easily distinguishable from cells freely flowing in the suspension that move much faster. Images of adhering leukocytes on the HUVEC surface were digitized and processed on a personal computer using general purpose image processing software (NIH Image, v. 1.43, Bethesda, MD). The number of rolling cells on HUVEC surface at 3.0 dynedcm' was determined on a series of 16 consecutive images digitized during a 10-second interval. Adherent leukocytes were identified and counted at the end of 13 minutes of perfusion.'"," All images were then superimposed by digital processing so that moving cells could be distinguished from their wake.
Statistical analysis. Results are expressed as the mean 2 SE. Statistical analysis was performed using analysis of variance and the Tukey-Cicchetti test for multiple group comparisons, as appropriate." Statistical significance was defined as P < .OS.
RESULTS
Effect of V T -I on leukocyte adhesion to HUVECs under physiologicjow conditions.
We have studied the adhesion of peripheral total leukocytes to control, VT-I -treated (0.1, 1, and 10 pmol/L), and IL-1P-treated (100 U/mL) HUVECs under flow conditions. We used VT-I at concentrations (chosen according to previous studies"') that did not affect cell morphology (Fig 1) and cell count after 24 hours of incubation (VT-I at 10 pmoVL: 69. The possibility that VT-1 -induced leukocyte adhesion could be due to endotoxin contamination of VT-I preparations was ruled out by experiments showing that the number of leukocytes adhering to HUVECs exposed for 24 hours to LPS was similar to that of control HUVECs (66 -+ 9 v 58 +-9 leukocytes/mm'). Figure 3 depicts digitized images from a representative experiment at the end of 13 minutes of leukocyte perfusion. A limited number of leukocytes firmly adhered to control HUVECs. A more than threefold increase in leukocyte adhesion was observed on HUVEC monolayers exposed for 24 hours to VT-I (10 pmol/L). A similar response was elicited by IL-lp, which is one of the most potent inducers of endothelial cell adhesive properties.
The number of leukocytes rolling at 3 dynes/cm* are reuse only. The number of rolling leukocytes on VT-I -treated (10 pmol/L) HUVECs incubated with MoAb against E-selectin, ICAM-I, and VCAM-I was similar to that observed on endothelial cells treated with VT-I alone (3.4 ? 1.5; 4.8 t 0.8; 3.1 _t 0.6 v 3.4 5 0.7 leukocytes/mm*).
Effect of TNF on VT-l -induced leukocyte adhesion to HCJVECs under physiologic Jlow conditions. In some experiments, before VT-I (IO pmol/L) incubation, HUVECs were pre-exposed for 24 hours to TNFa at the concentration of 100 U/mL, which was previously shown to increase VT-I receptor expression on HUVECS" (Fig 6) . VT-I significantly enhanced leukocyte adhesion on HUVECs as compared with control cells (146 2 15 v 45 t 5 leukocytes/mm*, P < .01).
The number of leukocytes adhering to HUVECs pre-exposed to TNFa before challenge with VT-I were significantly higher than that of HUVECs exposed to VT-I alone (300 t 13 v 146 t 15 leukocyteslmm', P < .01 ). The number of leukocytes adhering on HUVECs exposed to TNFa ( 1 0 0 U/ mL) alone averaged 201 t 29 leukocytes/mm' ( P < .01 v
With additional experiments we established that leukocyte adhesion on HUVECs reached a plateau at a TNFa concentration of 300 U/mL (control, 71.2 t 6.8; 100 U/mL TNFa, 162.4 t 13.5; 300 U/mL TNFa, 286.2 t 13.6; 500 U/mL TNFa, 268.0 t 10.7 leukocytes/mm'). When HUVECs pretreated with 300 U/mL TNFa were exposed to VT-I (IO TNFu + VT-l ). conditions. The adhesive response elicited by VT-I was quite comparable to that of IL-ID, one of the most potent inducers of leukocyte-endothelial cell adhesion. Because leukocyte attachment consistently induces granule content release,23 the present study helps to clarify mechanism(s) by which VT-I damages the endothelium. These results are in harmony with data that in vitro HUS neutrophils adhere to endothelium more than normal neutrophils."' Neutrophil-derived products (particularly elastase) that are released locally on neutrophil adhesion to endothelium degrade extracellular matrix, which would favor endothelial cell detachment from basement membrane, a typical feature of HUS." Formal evidence that this may occur in HUS derives from data that enhanced adhesion of neutrophils from HUS patients to endothelium in vitro is followed by degradation of endothelial cell fibronectin.'" Events that regulate recruitment of leukocytes and subsequent migration are critically dependent on adhesive molecules constitutively expressed on the surface of the endothelium and leukocytes or induced by cytokines or flow Early molecules involved in this process belong to the selectin family?"'3? and are expressed on endothe- blocking of E-selectin, ICAM-l, and VCAM-1 with respective antibodies significantly reduced VT-l -mediated leukocyte adhesion to endothelial cells exposed to flow. An additional finding of the present study was that VT-l inhibited the process of rolling that normally precedes adhesion of cells to the endothelium. We observed a similar phenomenon in tumor cell adhesion to the endothelium under flow.*' It was established that certain lines (ie. A375M and A2058 melanomas and the MG-63 osteosarcoma) firmly adhered on activated endothelial cells before any rolling could be seen, whereas other lines (HT-29M colon carcinoma and OVCAR-3 ovarian carcinoma) were capable of usual rolling before they adhered. It is tempting to speculate that VT-I causes sudden expression of ICAM-l and VCA"1 at very high density on endothelial cell surface, which would promote immediate leukocyte adhesion not preceded by rolling. The last observation of the present study was that pre-exposure of HUVECs to TNFa before challenge with VT-l significantly increased the number of adherent leukocytes under flow. This observation is consistent with several recent findings
that TNFa does promote upregulation of endothelial VTGb3 receptor and supports VT-l binding.'" That TNFa plays a major role in VT-1 -induced microvascular injury is documented by findings that mice genetically defective in TNFa production were less sensitive to the lethal effects of VT-1." These mice consistently had a longer mean time to death than did mice who were normally responsive. The molecular basis for the interaction between VT-l and TNFa in determing extent and localization of microvascular lesions were recently addressed in an elegant experiment of mice bearing a chloroamphenicol acetyl-transferase (CAT) reporter gene that indicates TNFa synthesis."6 Upon VT-l injection to the above-mentioned mice, CAT activity was selectively induced in the kidney but not in other organs, indicating a distinct potential of VT-1 of upregulating TNFa gene expression not equally distributed within all organs, which fits well with the unique sensitivity of the kidney to microvascular damage in HUS.
In conclusion, our results indicate that (1) VT-1 is a potent promoter of leukocyte adhesion to endothelial cells under use only.
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